ProMRI PROVEN Master Study

NCT ID: NCT01809665

Last Updated: 2016-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

174 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigation is designed to provide supporting evidence for the clinical safety of the Ilesto/Iforia ICD (implantable cardioverter-defibrillator)system and the Evia/Entovis HF-T (Heart Failure) triple chamber pacemaker system when used under specific MRI (magnetic resonance imaging) conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICD/CRT-P therapy

Standard indication for ICD or triple-chamber pacemaker therapy

ICD/CRT-P therapy

Intervention Type DEVICE

MRI

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICD/CRT-P therapy

Intervention Type DEVICE

MRI

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ilesto 7/5 Iforia 7/5 Evia HF-T Entovis HF-T Solia S Solia T Linoxsmart ProMRI S, SD or S DX Linoxsmart ProMRI DF4 SD Corox ProMRI OTW BP, -S BP or -L BP Protego ProMRI SD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Able and willing to complete MRI testing
* Able and willing to activate and use the Cardio Messenger
* Able and willing to complete all testing required by the clinical protocol
* Available for all follow-up visits at the investigational site
* Standard indication for single, dual, or triple chamber ICD or CRT-P.
* ICD or CRT-P system to be implanted in the pectoral region
* Patient body height ≥ 140 cm
* Age ≥ 18 years

Exclusion Criteria

* Standard contraindication for single, dual, or triple chamber ICD or CRT-P.
* Systems with an atrial lead: The patient has persistent (lasting longer than 7 days or requiring cardioversion) or permanent atrial arrhythmia
* Patient has other medical implants that may interact with MRI, e.g. abandoned pacemaker/ICD leads, lead extensions, mechanical valves, other active medical devices, non-MRI compatible devices
* Patient has other metallic artifacts / components in body that may interact with MRI
* Life expectancy of less than eight months
* Cardiac surgery in the next eight months
* Pregnant or breastfeeding
* Enrolled in another non-observational cardiac clinical investigation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik SE & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wolfgang R. Bauer, Prof.Dr.Dr.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik I, Oberdürrbacher Str. 6, 97080 Würzburg, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Flinders Medical Center

Bedford Park, South Australia, Australia

Site Status

Box Hill Hospital

Box Hill, Victoria, Australia

Site Status

Royal Adelaide Hospital

Adelaide, , Australia

Site Status

Royal Perth Hospital

Perth, , Australia

Site Status

Royal North Shore Hospital

Sydney, , Australia

Site Status

AKH Linz

Linz, , Austria

Site Status

Landesklinikum St. Pölten

Sankt Pölten, , Austria

Site Status

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Montreal Heart Institute

Montreal, Quebec, Canada

Site Status

CHUS - Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Site Status

Royal Alexandra Hospital

Edmonton, , Canada

Site Status

University Hospital Olomouc

Olomouc, , Czechia

Site Status

CHU Brest

Brest, , France

Site Status

CHRU de Tours - Hopital Trousseau

Tours, , France

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Klinikum Coburg

Coburg, , Germany

Site Status

Elisabeth Krankenhaus Essen

Essen, , Germany

Site Status

Schwarzwald Baar Klinikum Villingen Schwenningen

Villingen-Schwenningen, , Germany

Site Status

Medizinische Universitätsklinik Würzburg

Würzburg, , Germany

Site Status

Semmelweis University

Budapest, , Hungary

Site Status

Stadtspital Triemli

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Canada Czechia France Germany Hungary Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

61

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BioMonitor Master Study
NCT01725568 COMPLETED
Linox Smart S DX PME/Master Study
NCT01090401 COMPLETED PHASE4
Iperia/Sentus QP Study
NCT02181686 COMPLETED
BIO|CONCEPT.Amvia Study
NCT05610176 COMPLETED NA
EMRI SureScan™ Clinical Study
NCT00433654 COMPLETED NA
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135 ACTIVE_NOT_RECRUITING NA
3T MRI CIED Post-Approval Study
NCT02969395 COMPLETED